Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Bloch

Showing results (41-50 of 87) with videos related to

Pageof 9
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|March 17, 2012
A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adultsDianne Carey, Sarah L Pett, Mark Bloch, et al.
Open Forum Infectious Diseases|November 3, 2025
Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at BaselineKaram Mounzer, Jihad Slim, Moti Ramgopal, et al.
HIV Clinical Trials|July 11, 2017
Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTIAnton Pozniak, Jason Flamm, Andrea Antinori, et al.
AIDS (London, England)|August 24, 2011
Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoirKersten K Koelsch, Christoph Boesecke, Kristin McBride, et al.
Lancet (London, England)|January 12, 2013
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 studyFrancois Raffi, Anita Rachlis, Hans-Jürgen Stellbrink, et al.
AIDS (London, England)|July 26, 2021
Renal impairment in a large-scale HIV preexposure prophylaxis implementation cohortDouglas Drak, Hamish Mcmanus, Tobias Vickers, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 26, 2024
Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex HIV Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1)Karam Mounzer, Jihad Slim, Moti Ramgopal, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 27, 2008
Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infectionSharon R Lewin, John M Murray, Ajantha Solomon, et al.
AIDS and Behavior|October 5, 2018
High Adherence to HIV Pre-exposure Prophylaxis and No HIV Seroconversions Despite High Levels of Risk Behaviour and STIs: The Australian Demonstration Study PrELUDEIryna B Zablotska, Stefanie J Vaccher, Mark Bloch, et al.
AIDS and Behavior|July 24, 2024
Condom Failure Among HIV-Negative Men in Serodiscordant Relationships in Australia, Brazil, and ThailandJames Gray, Garrett Prestage, Fengyi Jin, et al.
Pageof 9

Showing results (41-50 of 87) with videos related to

Sort By:
Pageof 9
Journal of Acquired Immune Deficiency Syndromes (1999)|March 17, 2012
A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adultsDianne Carey, Sarah L Pett, Mark Bloch, et al.
Open Forum Infectious Diseases|November 3, 2025
Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at BaselineKaram Mounzer, Jihad Slim, Moti Ramgopal, et al.
HIV Clinical Trials|July 11, 2017
Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTIAnton Pozniak, Jason Flamm, Andrea Antinori, et al.
AIDS (London, England)|August 24, 2011
Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoirKersten K Koelsch, Christoph Boesecke, Kristin McBride, et al.
Lancet (London, England)|January 12, 2013
Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 studyFrancois Raffi, Anita Rachlis, Hans-Jürgen Stellbrink, et al.
AIDS (London, England)|July 26, 2021
Renal impairment in a large-scale HIV preexposure prophylaxis implementation cohortDouglas Drak, Hamish Mcmanus, Tobias Vickers, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 26, 2024
Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex HIV Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1)Karam Mounzer, Jihad Slim, Moti Ramgopal, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 27, 2008
Virologic determinants of success after structured treatment interruptions of antiretrovirals in acute HIV-1 infectionSharon R Lewin, John M Murray, Ajantha Solomon, et al.
AIDS and Behavior|October 5, 2018
High Adherence to HIV Pre-exposure Prophylaxis and No HIV Seroconversions Despite High Levels of Risk Behaviour and STIs: The Australian Demonstration Study PrELUDEIryna B Zablotska, Stefanie J Vaccher, Mark Bloch, et al.
AIDS and Behavior|July 24, 2024
Condom Failure Among HIV-Negative Men in Serodiscordant Relationships in Australia, Brazil, and ThailandJames Gray, Garrett Prestage, Fengyi Jin, et al.
Pageof 9